Table 3.
VcR-CAP versus R-CHOP: Progression-Free Survival in Previously Untreated Mantle-Cell Lymphoma
| Efficacy end point | VcR-CAP (N = 243) |
R-CHOP (N = 244) |
|---|---|---|
| Progression-free survivala | ||
| Events, N (%) | 133 (55) | 165 (68) |
| Median, mo | 25 (95% CI, 20–32) | 14 (95% CI, 12–17) |
| Hazard ratio | 0.63 (95% CI, 0.50–0.79) | |
| P <.001 | ||
a
By independent radiographic assessment.
CI indicates confidence interval; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone.
Source: Velcade (bortezomib) for injection prescribing information; October 2014.